Denali Therapeutics Inc. $DNLI Position Cut by Baillie Gifford & Co.

Baillie Gifford & Co. decreased its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 3.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 11,591,585 shares of the company’s stock after selling 363,738 shares during the quarter. Baillie Gifford & Co. owned about 0.08% of Denali Therapeutics worth $168,310,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the company. Headlands Technologies LLC bought a new stake in Denali Therapeutics in the 2nd quarter valued at about $26,000. State of Wyoming bought a new stake in shares of Denali Therapeutics in the 2nd quarter worth $29,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Denali Therapeutics by 15.5% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,612 shares of the company’s stock valued at $79,000 after buying an additional 753 shares during the period. PNC Financial Services Group Inc. lifted its holdings in shares of Denali Therapeutics by 120.1% in the second quarter. PNC Financial Services Group Inc. now owns 8,236 shares of the company’s stock valued at $115,000 after buying an additional 4,494 shares during the period. Finally, Ameritas Investment Partners Inc. boosted its stake in Denali Therapeutics by 7.4% during the second quarter. Ameritas Investment Partners Inc. now owns 13,522 shares of the company’s stock valued at $189,000 after buying an additional 930 shares in the last quarter. Institutional investors own 92.92% of the company’s stock.

Insider Activity

In other Denali Therapeutics news, CEO Ryan J. Watts sold 35,198 shares of the company’s stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total value of $580,767.00. Following the transaction, the chief executive officer owned 296,833 shares in the company, valued at approximately $4,897,744.50. This represents a 10.60% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Alexander O. Schuth sold 17,218 shares of Denali Therapeutics stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total value of $284,097.00. Following the sale, the insider directly owned 282,828 shares of the company’s stock, valued at approximately $4,666,662. The trade was a 5.74% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 12.50% of the company’s stock.

Analyst Upgrades and Downgrades

DNLI has been the topic of several research reports. Morgan Stanley reiterated an “overweight” rating and issued a $40.00 price target on shares of Denali Therapeutics in a research report on Thursday, January 8th. Stifel Nicolaus set a $37.00 target price on shares of Denali Therapeutics in a report on Monday, November 17th. Wedbush reduced their target price on shares of Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating for the company in a report on Thursday, December 11th. JPMorgan Chase & Co. lifted their price target on shares of Denali Therapeutics from $24.00 to $26.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 4th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $32.00 price target on shares of Denali Therapeutics in a report on Friday, December 5th. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $32.77.

Denali Therapeutics Stock Down 3.2%

DNLI stock opened at $20.25 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.79 and a quick ratio of 9.79. The firm has a market capitalization of $2.97 billion, a P/E ratio of -6.96 and a beta of 1.05. Denali Therapeutics Inc. has a 52-week low of $10.57 and a 52-week high of $24.34. The company’s 50 day simple moving average is $17.88 and its 200-day simple moving average is $15.96.

Denali Therapeutics (NASDAQ:DNLI) last released its earnings results on Thursday, November 6th. The company reported ($0.74) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.02. Denali Therapeutics’s quarterly revenue was up .0% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.63) earnings per share. As a group, equities research analysts anticipate that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.